Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


26.11.2018

1 Am J Clin Oncol
1 Anal Chim Acta
1 Biochem Biophys Res Commun
1 Bioorg Med Chem Lett
1 BJU Int
1 BMC Cancer
1 Cell Physiol Biochem
1 Clin Transl Imaging
1 Cureus
1 Exp Cell Res
1 Exp Mol Med
1 Front Oncol
1 Hum Gene Ther
1 Hum Pathol
1 Indian J Pathol Microbiol
1 Int J Biol Sci
1 Int J Urol
1 J Ayub Med Coll Abbottabad
1 J Urol
1 JAMA Netw Open
1 Med Sci Monit
1 Mol Cancer
1 Pan Afr Med J
1 Transl Androl Urol
1 Urol Int
11 Urol Oncol
1 Urology
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. HAMMER L, Laufer M, Dotan Z, Leibowitz-Amit R, et al
    Accelerated Hypofractionated Radiation Therapy for Elderly Frail Bladder Cancer Patients Unfit for Surgery or Chemotherapy.
    Am J Clin Oncol. 2018 Nov 16. doi: 10.1097/COC.0000000000000491.
    PubMed     Text format     Abstract available


    Anal Chim Acta

  2. LIANG L, Wang Y, Lu S, Kong M, et al
    Microchips for detection of exfoliated tumor cells in urine for identification of bladder cancer.
    Anal Chim Acta. 2018;1044:93-101.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  3. WANG F, Zu Y, Zhu S, Yang Y, et al
    Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression.
    Biochem Biophys Res Commun. 2018 Nov 12. pii: S0006-291X(18)32411.
    PubMed     Text format     Abstract available


    Bioorg Med Chem Lett

  4. BOTTA L, Filippi S, Bizzarri BM, Meschini R, et al
    Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines.
    Bioorg Med Chem Lett. 2018 Nov 7. pii: S0960-894X(18)30862.
    PubMed     Text format     Abstract available


    BJU Int

  5. MUNARI E, Calio A, Brunelli M, Martignoni G, et al
    Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology.
    BJU Int. 2018;122:914-915.
    PubMed     Text format    


    BMC Cancer

  6. WANG L, Chen S, Zhang Z, Zhang J, et al
    Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer.
    BMC Cancer. 2018;18:1141.
    PubMed     Text format     Abstract available


    Cell Physiol Biochem

  7. ZHANG J, Wang L, Mao S, Liu M, et al
    miR-1-3p Contributes to Cell Proliferation and Invasion by Targeting Glutaminase in Bladder Cancer Cells.
    Cell Physiol Biochem. 2018;51:513-527.
    PubMed     Text format     Abstract available


    Clin Transl Imaging

  8. SALMANOGLU E, Halpern E, Trabulsi EJ, Kim S, et al
    A glance at imaging bladder cancer.
    Clin Transl Imaging. 2018;6:257-269.
    PubMed     Text format     Abstract available


    Cureus

  9. POPOV H, Donev IS, Ghenev P
    Quantitative Analysis of Tumor-associated Tissue Eosinophilia in Recurring Bladder Cancer.
    Cureus. 2018;10:e3279.
    PubMed     Text format     Abstract available


    Exp Cell Res

  10. LUAN T, Fu S, Huang L, Zuo Y, et al
    MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells.
    Exp Cell Res. 2018;373.
    PubMed     Text format     Abstract available


    Exp Mol Med

  11. OU Z, Wang Y, Chen J, Tao L, et al
    Estrogen receptor beta promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals.
    Exp Mol Med. 2018;50:152.
    PubMed     Text format     Abstract available


    Front Oncol

  12. CHENG X, Liu X, Liu X, Guo Z, et al
    Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
    Front Oncol. 2018;8:494.
    PubMed     Text format     Abstract available


    Hum Gene Ther

  13. ZHEN S, Lu J, Chen W, Zhao L, et al
    Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
    Hum Gene Ther. 2018 Nov 19. doi: 10.1089/hum.2018.
    PubMed     Text format     Abstract available


    Hum Pathol

  14. YIN H, He W, Li Y, Xu N, et al
    Loss of DUSP2 predicts a poor prognosis in patients with bladder cancer.
    Hum Pathol. 2018 Nov 17. pii: S0046-8177(18)30440.
    PubMed     Text format     Abstract available


    Indian J Pathol Microbiol

  15. GONUL II, Cakir A, Sozen S
    Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder.
    Indian J Pathol Microbiol. 2018;61:350-355.
    PubMed     Text format     Abstract available


    Int J Biol Sci

  16. WANG Y, Hao F, Nan Y, Qu L, et al
    PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis.
    Int J Biol Sci. 2018;14:1883-1891.
    PubMed     Text format     Abstract available


    Int J Urol

  17. MIYAKE M, Nakai Y, Hori S, Morizawa Y, et al
    Transient liver toxicity as a result of the oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2018 Nov 18. doi: 10.1111/iju.13856.
    PubMed     Text format    


    J Ayub Med Coll Abbottabad

  18. RIAZ A, Khan K, Afreen B, Kazmi I, et al
    Bladder Cancer In Patients With Type 2 Diabetes Treated With Pioglitazone, A Comparative Study.
    J Ayub Med Coll Abbottabad. 2018;30:356-359.
    PubMed     Text format     Abstract available


    J Urol

  19. CHANG SS
    Re: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
    J Urol. 2017;197:53-54.
    PubMed     Text format    


    JAMA Netw Open

  20. SCHROECK FR, Lynch KE, Chang JW, MacKenzie TA, et al
    Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer.
    JAMA Netw Open. 2018;1.
    PubMed     Text format     Abstract available


    Med Sci Monit

  21. YANG T, Li Y, Li J, Liu J, et al
    Diagnostic Value Comparison of Urothelium Carcinoma Among Urine Exfoliated Cells Fluorescent In Situ Hybridization (FISH) Examination, Computerized Tomography (CT) Scan, and Urine Cytologic Examination.
    Med Sci Monit. 2018;24:5788-5792.
    PubMed     Text format     Abstract available


    Mol Cancer

  22. LIU H, Bi J, Dong W, Yang M, et al
    Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis.
    Mol Cancer. 2018;17:161.
    PubMed     Text format     Abstract available


    Pan Afr Med J

  23. AKDENIZ E, Bakirtas M, Bolat MS, Akdeniz S, et al
    Pure large cell neuroendocrine carcinoma of the bladder without urological symptoms.
    Pan Afr Med J. 2018;30:134.
    PubMed     Text format     Abstract available


    Transl Androl Urol

  24. SHANKAR PR, Barkmeier D, Hadjiiski L, Cohan RH, et al
    A pictorial review of bladder cancer nodal metastases.
    Transl Androl Urol. 2018;7:804-813.
    PubMed     Text format     Abstract available


    Urol Int

  25. SANGUEDOLCE F, Russo D, Mancini V, Selvaggio O, et al
    Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review.
    Urol Int. 2018 Nov 21:1-13. doi: 10.1159/000494359.
    PubMed     Text format     Abstract available


    Urol Oncol

  26. JOHNSON SC, Smith ZL, Golan S, Rodriguez JF 3rd, et al
    Perioperative and long-term outcomes after radical cystectomy in hemodialysis patients.
    Urol Oncol. 2018;36:237.
    PubMed     Text format     Abstract available

  27. FALKE J, Hulsbergen-van de Kaa CA, Maj R, Oosterwijk E, et al
    Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model.
    Urol Oncol. 2018;36:242.
    PubMed     Text format     Abstract available

  28. WERNTZ RP, Martinez-Acevedo A, Amadi H, Kopp R, et al
    Prophylactic antibiotics following radical cystectomy reduces urinary tract infections and readmission for sepsis from a urinary source.
    Urol Oncol. 2018 Jan 12. pii: S1078-1439(17)30654.
    PubMed     Text format     Abstract available

  29. FANTINI D, Seiler R, Meeks JJ
    Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients.
    Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30381.
    PubMed     Text format     Abstract available

  30. JIANG H, Bu Q, Zeng M, Xia D, et al
    MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF.
    Urol Oncol. 2018 Nov 16. pii: S1078-1439(18)30295.
    PubMed     Text format     Abstract available

  31. ELSAWY AA, El-Assmy AM, Bazeed MA, Ali-El-Dein B, et al
    The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
    Urol Oncol. 2018 Nov 14. pii: S1078-1439(18)30403.
    PubMed     Text format     Abstract available

  32. RAY-ZACK MD, Shan Y, Mehta HB, Yu X, et al
    Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model.
    Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30431.
    PubMed     Text format     Abstract available

  33. XU Y, Kim YH, Jeong P, Piao XM, et al
    Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
    Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30429.
    PubMed     Text format     Abstract available

  34. JURACEK J, Stanik M, Vesela P, Radova L, et al
    Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30397.
    PubMed     Text format     Abstract available

  35. MARCH-VILLALBA JA, Ramos-Soler D, Soriano-Sarrio P, Hervas-Marin D, et al
    Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30386.
    PubMed     Text format     Abstract available

  36. HURST CD, Knowles MA
    Mutational landscape of non-muscle-invasive bladder cancer.
    Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30398.
    PubMed     Text format     Abstract available


    Urology

  37. BAI S, Yao Z, Zhu X, Li Z, et al
    The feasibility and safety of reproductive organ preserving radical cystectomy for elderly female patients with muscle invasive bladder cancer: a retrospective propensity score-matched study.
    Urology. 2018 Nov 13. pii: S0090-4295(18)31139.
    PubMed     Text format     Abstract available


    World J Urol

  38. MOSSANEN M, Wang Y, Szymaniak J, Tan WS, et al
    Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.
    World J Urol. 2018 Nov 16. pii: 10.1007/s00345-018-2550.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: